Skip Navigation Links
Skip navigation links
Main Homepage
Biomed Research Home
Analytical Biochemistry
Tyrosine Hydroxylase
Adenosine-5-triphosphate
Biogenic Polyamines
Lipid Peroxidation
Molecular Biology
GFAP mRNA Expression
HLA-C Genotyping
Clinical Biochemistry
Diabetes
Psoriasis
Septic Shock
Nephrotoxicity
Neurosciences
Dyskinetic Syndrome
Parkinson's Disease
Huntington's Disease
Neurotrauma
Gastroenterology
Pharmacotherapy
Ulcer Quantification
Environmental Health
Benzene
Pesticides

Huntington’s Disease

 

Huntington’s disease (HD) is a chronic progressive autosomal dominant neurodegenerative disorder that is characterized by striatal-specific degeneration. In spite of extensive research this devastating hereditary disease remains incurable, warranting further studies to determine the cause and cure of HD. It has been reported that nicotinic acetylcholine receptor (nAchR) in the central nervous system (CNS) is a new potential therapeutic target for the management of neurodegenerative diseases.

 

 

 

Figure. Tyrosine hydroxylase immunostaining of the striatal dopaminergic neurons. (A) Normal (B) 3-NP treated rats.

 

We have demonstrated the protective effects of nAchR agonist, nicotine, against 3-nitropropionic acid (3-NP) induced biochemical, behavioral and histological changes in a rat model of Huntington’s disease [1]. Our findings further new insights of the mechanisms of HD that might help to design novel therapies for this disabling neurodegenerative disease.

  1. Mohamed T, Khan HA, Elfaki I, Al Deeb S, Al Moutaery K. Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington’s disease in rats. Brain Res Bull 2005; 67: 161-168.

King   Saud University. All rights reserved, 2007 | Disclaimer | CiteSeerx